Market: NASD |
Currency: USD
Address: One World Trade Center
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
📈 Mind Medicine (MindMed) Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$25.00
-
Upside/Downside from Analyst Target:
153.81%
-
Broker Call:
21
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-01
-
EPS Estimate:
-0.70
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2022 |
- |
$0.066667 |
- |
2022-08-29 |
- |
Stock split |
|
Total Amount for 2022: $0.066667 |
📅 Earnings & EPS History for Mind Medicine (MindMed) Inc.
| Date | Reported EPS |
|---|
| 2025-10-31 (estimated upcoming) | - |
| 2025-07-31 | -0.5 |
| 2025-05-08 | -0.35 |
| 2025-03-06 | -0.41 |
| 2024-11-07 | -0.18 |
| 2024-08-13 | -0.29 |
| 2024-05-08 | -1.14 |
| 2024-02-28 | -0.59 |
| 2023-11-02 | -0.45 |
| 2023-08-03 | -0.76 |
| 2023-05-04 | -0.65 |
| 2023-03-09 | -0.27 |
| 2022-11-10 | -0.56 |
| 2022-08-11 | -0.6 |
| 2022-05-16 | -0.6 |
| 2022-03-28 | -0.75 |
| 2021-11-12 | -0.9 |
| 2021-08-12 | -1.35 |
| 2020-11-12 | -0.45 |
📰 Related News & Research
No related articles found for "mind medicine".
